Prescribing Pattern with Treatment Approaches and Mortality Risk Assessment Using the Charlson Comorbidity Index in Head and Neck Cancer
Abstract
Background: Head and neck cancer (HNC) is a major health challenge in India, which is mainly caused by improper lifestyle and poor social economic status where its treatment choice is mainly dependent on the situation and comorbidity of the patient. Objective: To study prescribing pattern along with treatment modalities in HNC and Assessment of 10-year mortality risk using the Charlson Comorbidity Index in a survey-based study population Methodology: This study was conducted over a period of 6 months in the Oncology Department of Karnataka Medical College and Research Institute, Hubballi, Karnataka, India. Results: A total of 150 cases were evaluated among most of the patients were male and aged between 50 to 69 years. The tobacco chewing is considered a leading cause to get HNC and around 90% of patients are diagnosed at an advanced stage (III–IV) with stage IVA (53.33%) as the most common. From the study it has been observed that about 77% of patients were given with multimodal therapy, among this platinum-based chemotherapy regimen are more common, followed by radiotherapy (71.33%) used as an adjuvant therapy after surgery. A significant association was observed between stage of cancer and treatment modality (χ² = 63.783, p = 0.0013) and Charlson Comorbidity Index showed that about 12.7 % patients have lesser than 50 % predicated mortality risk. Conclusion: The report finds that stage at diagnosis significantly influences treatment selection, with advanced stages requiring multimodal platinum-based therapy and radiotherapy and with respect to mortality risk , age of the patient significantly influences the mortality risk were as gender has no significance with respect to mortality risk and the predominance of low CCI scores in 87.3% patients indicates a favourable prognostic profile, highlighting the value of combining stage-based treatment with comorbidity assessment for individualized clinical decision-making.
Keywords: Head and neck cancer, prescribing pattern, treatment modalities, platinum-based chemotherapy, Charlson Comorbidity Index.
Keywords:
head and neck cancer , prescribing pattern, treatment modalities, platinum-based chemotherapy, Charlson Comorbidity IndexDOI
https://doi.org/10.22270/jddt.v16i9.7969References
1. Dhull AK, Atri R, Dhankhar R, Chauhan AK, Kaushal V. Major risk factors in head and neck cancer: A retrospective analysis of 12-year experiences. World J Oncol. 2018;9(3):80-84. https://doi.org/10.14740/wjon1104w PMid:29988794 PMCid:PMC6031231
2. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. https://doi.org/10.3322/caac.21834 PMid:38572751
3. Bagal S, Budukh A, Thakur JS, Dora T, Qayyumi B, Khanna D, et al. Head and neck cancer burden in India: An analysis from published data of 37 population-based cancer registries. Ecancermedicalscience. 2023;17:1603. https://doi.org/10.3332/ecancer.2023.1603 PMid:37799939 PMCid:PMC10550331
4. Constantin M, Chifiriuc MC, Bleotu C, Vrancianu CO, Cristian RE, Bertesteanu SV, et al. Molecular pathways and targeted therapies in head and neck cancers pathogenesis. Front Oncol. 2024;14. https://doi.org/10.3389/fonc.2024.1373821 PMid:38952548 PMCid:PMC11215092
5. Bhosle J, Hall G. Principles of cancer treatment by chemotherapy. Surgery (Oxford). 2009;27(4):173-177. https://doi.org/10.1016/j.mpsur.2009.01.006
6. Vaidya JS. Principles of cancer treatment by radiotherapy. Surgery (Oxford). 2024;42(3):139-149. https://doi.org/10.1016/j.mpsur.2023.12.001
7. King AT, Primrose J. Principles of cancer treatment by surgery. Surgery (Oxford). 2003;21(11):284-288. https://doi.org/10.1383/surg.21.11.284.22291
8. Syrigos KN, Karachalios D, Karapanagiotou EM, Nutting CM, Manolopoulos L, Harrington KJ. Head and neck cancer in the elderly: An overview of treatment modalities. Cancer Treat Rev. 2009;35(3):237-245. https://doi.org/10.1016/j.ctrv.2008.11.002 PMid:19100689
9. Mathew A, Chibueze NI, Sukumar TM, Mahadevamma L, Alsanas T. A study on prescribing pattern of chemotherapy in head and neck cancer. Human J. 2020;18(3):463-486.
10. Larizadeh MH, Damghani MA, Shabani M. Epidemiological characteristics of head and neck cancers in southeast Iran. Iran J Cancer Prev. 2014;7(2):80-86.
11. Agarwal AK, Sethi A, Sareen D, Dhingra S. Treatment delay in oral and oropharyngeal cancer in our population: The role of socioeconomic factors and health-seeking behaviour. Indian J Otolaryngol Head Neck Surg. 2011;63(2):145-150. https://doi.org/10.1007/s12070-011-0134-9 PMid:22468251 PMCid:PMC3102173
12. Wahab A, Dalal K, Abedin M, Rakhshanda S, Mashreky SR. Prevalence of betel nut chewing and its pattern of distribution across Bangladeshi sociodemographics. Bangladesh Health and Injury Survey. 2016.
13. Nascimento de Carvalho F, Costa I, Dias F, Bergmann A, Pinto LFR. Disparities in stage at diagnosis of head and neck tumours in Brazil: A comprehensive analysis of hospital-based cancer registries. BMC Cancer. 2024;24:1062. https://doi.org/10.1016/j.lana.2024.100986 PMid:39877309 PMCid:PMC11773251
14. Anderson G, Ebadi M, Vo K, Novak J, Govindarajan A, Amini A. An updated review on head and neck cancer treatment with radiation therapy. Cancers (Basel). 2021;13(19):4912. https://doi.org/10.3390/cancers13194912 PMid:34638398 PMCid:PMC8508236
15. Tuljapurkar V, Dhar H, Mishra A, Chakraborti S, Chaturvedi P, Pai PS. The Indian scenario of head and neck oncology: Challenging the dogmas. South Asian J Cancer. 2016;5(3):105-107. https://doi.org/10.4103/2278-330X.187573 PMid:27606292 PMCid:PMC4991127
16. Sauriasari R, Bachtiar I, Putri RA. Antiemetic prophylaxis in head and neck cancer chemotherapy: Ondansetron (100%) and dexamethasone (83.1%) usage in 177 cycles. Indones J Cancer. 2025;19(2):282-288. https://doi.org/10.33371/ijoc.v19i2.1361
17. Cohen SM, Kim J, Roy N, Courey M. Prescribing patterns of primary care physicians and otolaryngologists in the management of laryngeal disorders. Otolaryngol Head Neck Surg. 2013;149(1):118-125. https://doi.org/10.1177/0194599813485360 PMid:23585154
18. Chuang EYH, Hou PY, Shueng PW, Lo WC, Lin PY, Lin SC, et al. Improved quality of life in head and neck cancer patients treated with modern arc radiotherapy techniques: A prospective longitudinal analysis. Front Oncol. 2024;14:1424034. https://doi.org/10.3389/fonc.2024.1424034 PMid:39376987 PMCid:PMC11456567
19. Singh B, Bhaya M, Stern J, Roland JT, Rosenfeld RM, Har-El G, et al. Validation of the Charlson comorbidity index in patients with head and neck cancer: A multi-institutional study. Laryngoscope. 1997;107(11):1469-1475. https://doi.org/10.1097/00005537-199711000-00009 PMid:9369392
20. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 2025 Plymouth Meeting (PA): National Comprehensive Cancer Network; 2025 [cited 2026 Mar 16]. Available from: https://www.nccn.org
21. Agarwal JP, Nemade B, Murthy V, Ghosh-Laskar S, Budrukkar A, Gupta T, et al. Hypofractionated, palliative radiotherapy for advanced head and neck cancer. Radiotherapy and Oncology. 2008 Oct;89(1):51-6. https://doi.org/10.1016/j.radonc.2008.06.007 PMid:18649963
22. SonaliBagal. Head and neck cancer burden in India: an analysis from published data of 37 population-based cancer registries. AtulBudukh, editor. ecancermedicalscience. 2023. https://doi.org/10.3332/ecancer.2023.1603 PMid:37799939 PMCid:PMC10550331
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83 https://doi.org/10.1016/0021-9681(87)90171-8 PMid:3558716
24. World Health Organization. Risk assessment and management in clinical practice. Geneva: World Health Organization; 2022.
25. Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating. New York: Springer; 2019. https://doi.org/10.1007/978-3-030-16399-0
26. Niccoli T, Partridge L. Ageing as a risk factor for disease. Curr Biol. 2012;22(17):R741-R752. https://doi.org/10.1016/j.cub.2012.07.024 PMid:22975005
27. Oksuzyan A, Juel K, Vaupel JW, Christensen K. Sex differences in health and mortality. Aging Clin Exp Res. 2008;20(2):91-100. https://doi.org/10.1007/BF03324754 PMid:18431075 PMCid:PMC3629373
Published
Abstract Display: 0 
PDF Downloads: 0 PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 J Sujan , Mallikarjunagouda Halakurki Bhavani , E Karegowdra Umesha , Shirguppi Rajshekar , V Bhat Shankar , Ashvini, Chetan B Savant, Preeti V. Kulkarni, M G Giriyappagoudar, Janaki R. Torvi , Venkatrao Kulkarni
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.